Study of SyntheCelTM Dura Replacement to Other Dura Replacements

Completed · Not applicable

Conditions studied: Cranial Dura Repair

In brief

Primary Objective: To demonstrate that the SyntheCelTM Dura Replacement performs similarly to or is substantially equivalent to other dura replacements for the repair of the cranial dura in patients undergoing surgical repair of the cranial dura.

Key facts

Study ID: NCT00859508
Run by: Synthes USA HQ, Inc.
People needed: 99
Starts: 2006-02-01
Expected to finish: 2009-01-01
Last updated by the study team: 2012-03-08

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patient is between 18 and 75 years of age
Patient is scheduled for an elective cranial procedure requiring a dural incision
Patient has an MRI no earlier than two months prior to the date of enrollment
Surgical wound is expected to be Class I/clean
Patient is available and willing to participate in the investigation for the duration of the study
Patient has signed a written Informed Consent to participate in the study prior to any study mandated determinations or procedures. This does not include MRIs that may be performed prior to obtaining informed consent.

You may not qualify if…

Patient has a cranial metallic implant(s) that would interfere with evaluation of the device or recovery
Patient is somnolent or comatose (Glasgow score< 8)
Patient has had a prior intracranial neurosurgical procedure in the same anatomical location
Patient will require use of a dural adhesive or sealant
Patient has known hydrocephalus
Patient's life expectancy is less than 6 months
Patient has a systemic infection (e.g. urinary tract infection (UTI), active pneumonia) or evidence of any surgical site infection, fever > 101°F, positive blood culture and/or a positive chest x-ray for acute infectious process
Patient has known allergy to device component (cellulose)
Patient is an acute cranial trauma surgical case
Patient has a local cranial infection
Patient has had chemotherapy and/or radiation treatment within 12 weeks prior to surgery, or has chemotherapy and/or radiation treatment planned 10 weeks post surgery
Patient has been clinically diagnosed with malignancy (other than basal cell carcinoma or low grade glioma), uncontrolled diabetes, sepsis, systemic collagen disease
Patient has creatinine levels > 2.0 mg/dL
Patient has total bilirubin level > 2.5 mg/dL
Patent has clinically significant coagulopathy with a partial thromboplastin time (PTT) ≥ 35, international normalized ratio (INR) ≥ 1.2, or is receiving Warfarin or Coumadin
Patient has a compromised immune system or autoimmune disease (white blood cell (WBC) count <4000/uL or >20,000/uL)
Patient is participating in another clinical trial using investigational devices/drugs
Patient is pregnant or breastfeeding or wishes to become pregnant during the course of the study
Patient is unable or unwilling to sign a consent form

Where it is running

Barrow Neurosurgical Institute — Scottsdale, Arizona, United States
Stanford Medical Center — Stanford, California, United States
University of Florida — Gainesville, Florida, United States
Oregon Health Sciences University — Portland, Oregon, United States
Allegheny General Hospital — Pittsburgh, Pennsylvania, United States
University of Texas — Houston, Texas, United States
University of Virginia — Charlottesville, Virginia, United States
West Virginia University School of Medicine — Morgantown, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.